

- **PREPRINT:** [10.1016/j.yfrne.2022.101017](https://doi.org/10.1016/j.yfrne.2022.101017)

How hormonal contraceptives shape brain function and behavior: a review of preclinical studies

Patrizia Porcu^a, Alessandra Concas^b, Mariangela Serra^b

^aNeuroscience Institute, National Research Council of Italy (CNR), Cagliari, Italy

*^bDepartment of Life and Environment Sciences, Section of Neuroscience and Anthropology,
University of Cagliari, Cagliari, Italy*

Corresponding Author:

Patrizia Porcu, Ph.D.

Neuroscience Institute

National Research Council of Italy (CNR)

Cittadella Universitaria, 09042 Monserrato, Cagliari, Italy

Phone: +39-070-6754163

Email: patrizia.porcu@in.cnr.it

Highlights

- Hormonal contraceptives (HC) affect brain function and behavior.
- We review preclinical studies on HC' effects on neurobehavior.
- Animal studies provide insights on HC' neurobiological effects.
- Understanding the neurobiological mechanisms of HC' actions will improve women's well-being.

Abstract

Steroid hormones influence different aspects of brain function, including development, neurogenesis, neuronal excitability, and plasticity, thus affecting emotional states, cognition, sociality, and reward. In women, their levels fluctuate across the lifespan and through the reproductive stages but are also altered by exogenous administration of hormonal contraceptives (HC). HC are widely used by women throughout their fertile life for both contraceptive and therapeutic benefits. However, awareness of their effects on brain function and behavior is still poorly appreciated, despite the emerging evidence of their action at the level of the central nervous system. Here, we summarize results obtained in preclinical studies aimed at investigating the neurobiological effects of HC. HC can alter neuroactive hormones, neurotransmitters, neuropeptides, as well as emotional states, cognition, social and sexual behaviors. Animal studies provide insights into the neurobiological effects of HC, with the aim to improve women's health and well-being.

Keywords: hormonal contraceptives; allopregnanolone; anxiety; depression; social behavior; sexual behavior; learning and memory; female rats

1. Introduction

Steroid hormones are crucial for normal brain function as they modulate brain development, neurogenesis, neuronal excitability, and neuronal plasticity, thus affecting emotional states, cognition, sociality, and reward. They exert these actions by binding to intracellular steroid receptors that promote gene transcription; in addition, some steroids can modulate ligand-gated ion channels located on the cell membrane thus exerting rapid non-genomic actions (McEwen and Milner, 2017; Porcu et al., 2016). Concentrations of endogenous steroid hormones fluctuate under several physiological conditions including development, puberty, the ovarian cycle, menopause, aging, as well as following several pathological conditions including neuropsychiatric diseases, neurodegenerative, inflammatory diseases, etc. In addition, several pharmacological treatments against these diseases can restore altered levels of steroids. Steroid levels, particularly sex steroids also vary in response to hormonal contraceptives (HC) use (Del Río et al., 2018; Porcu et al., 2016; Porcu et al., 2019).

HC are used by 43% of women of reproductive age worldwide, mostly to prevent unintended pregnancies (United Nations, 2019). Since the first oral contraceptive developed in the 1960s, “the pill”, several forms of hormonal contraception are now available, including injectable formulations, subcutaneous implants, skin patches, intrauterine devices, and vaginal rings. Oral contraceptives remain one of the most used forms of hormonal contraception, especially in western countries (United Nations, 2019), mostly due to their high efficacy and rapid reversibility; in addition, they are prescribed as treatment for some gynecological diseases, such as endometriosis, polycystic ovary syndrome, dysmenorrhea, acne, and hirsutism.

Given that HC are mostly used by young, healthy women, much attention should be paid to their side effects. In addition to the well-characterized cardiovascular adverse effects and potential risks for cervical and breast cancer, their use in some women is also associated with headache, weight gain, nausea, changes in menstrual flow and decreased sexual desire, suggestive of an effect at the level of

the central nervous system. Furthermore, emotional lability, irritability, and episodes of affective disorders such as depression or mood changes are also common reasons given by women for discontinuing effective HC use, often within the first three months, suggesting psychological effects of these drugs (Kulkarni, 2007; Kurshan and Epperson, 2006). Nonetheless, despite the large number of studies, there is still a lack of agreement on the effect of HC on mood disturbances, with evidence for mood deterioration as well as mood improvement or stabilization (Bitzer et al., 2018; Böttcher et al., 2012; Cheslack-Postava et al., 2015; Fruzzetti and Fidecicchi, 2020; Hall et al., 2012; Keyes et al., 2013; Lewis et al., 2019; Lundin et al., 2017; Rapkin et al., 2006a; Rapkin et al., 2006b; Robakis et al., 2019; Skovlund et al., 2016; Sundstrom Poromaa and Segeblad, 2012; Toffol et al., 2012). Indeed, brain imaging studies in women showed that HC induce microstructural changes and modify volumes in specific brain regions, along with altered functional connectivity in the frontal nodes of the executive network, with important consequences for emotional regulation (De Bondt et al., 2013; Lisofsky et al., 2016; Petersen et al., 2014; Petersen et al., 2015; Pletzer et al., 2016; Pletzer et al., 2019; Pletzer et al., 2010; Taylor et al., 2021). Some of these effects differ between adolescent and adult HC users (Sharma et al., 2020a; Sharma et al., 2020b), may worsen with the duration of HC use and may not be completely reversible (Pletzer and Kerschbaum, 2014).

Although it is now accepted that HC affect brain function, the mechanisms underlying such effects are not completely understood. Animal models may aid in investigating the neurobiological mechanisms behind HC' actions on brain function, but insofar very few studies have examined the effects of HC in animals' brains. Here, we describe the current literature on preclinical studies in animals focused on the effects of HC on the central nervous system.

2. Hormonal contraceptives alter levels of neuroactive steroid hormones

The HC pill is a combination of synthetic estrogens and progestins (combined oral contraceptives). Ethinyl estradiol (EE) is still the most used synthetic estrogen, even though some preparations using estradiol valerate or estetrol have the same contraceptive action with less side effects than EE (Apter et al., 2017; Nappi et al., 2014). Estrogens are paired to different types of progestins, including androgenic nortestosterone derivatives (levonorgestrel (LNG), norethindrone, desogestrel, gestodene, norgestimate), anti-androgenic progesterone derivatives (cyproterone acetate, chlormadinone acetate, nomegestrol acetate), and the spironolactone derivative drospirenone (Mitchell and Welling, 2020; Sitruk-Ware and Nath, 2010). Progestin-only contraceptives are also available as pills, injections, subdermal implants, and intrauterine devices. Emergency contraception also consists of a single administration of a higher dose of progestins, mostly LNG 1.5 mg or ulipristal acetate 30 mg (Regidor, 2018).

HC prevent ovulation by inhibiting the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, and estradiol and progesterone from the ovary, thus preventing the fluctuations in circulating levels of such hormones that typically occur throughout the menstrual cycle (Lobo and Stanczyk, 1994). Furthermore, HC prevent the increase in serum levels of pregnenolone, testosterone and the progesterone derivative, allopregnanolone (($3\alpha,5\alpha$)-3-hydroxypregnan-20-one or $3\alpha,5\alpha$ -THP), typically observed in the luteal phase of the menstrual cycle in women (Follesa et al., 2002; Paoletti et al., 2004; Rapkin et al., 2006b). The neuroactive steroid allopregnanolone regulates mood, emotional states, the stress response, and its levels are altered in several neuropsychiatric diseases, including anxiety, depression, premenstrual dysphoric disorder, post-traumatic stress disorder, or alcohol use disorders (Bäckström et al., 2014; Girdler et al., 2012; Porcu and Morrow, 2014; Rasmusson et al., 2017). Interestingly, its synthetic form brexanolone has recently gained FDA approval for treatment of post-partum depression (Meltzer-Brody et al., 2018), and allopregnanolone has been proposed as a

therapeutic approach for alcohol use disorders and stress-related diseases (Boero et al., 2020; Morrow et al., 2020).

Similar to the effects in women, HC also disrupt the rat estrous cycle, inhibiting ovulation and decreasing levels of neuroactive steroid hormones. Long-term administration of EE alone or in combination with different progestins decreased basal and GnRH-stimulated serum LH levels in intact female rats, and this latest effect normalized two weeks after drug discontinuation (Kuhl et al., 1984). In agreement, we reported that long-term administration (up to 6 weeks) of EE (30 µg), LNG (125 µg), and their combination (EE-LNG) markedly decreased plasma, cerebrocortical and hippocampal levels of pregnenolone, progesterone and allopregnanolone, and that levels of such hormones returned to normal two weeks after HC discontinuation (Follesa et al., 2002; Porcu et al., 2012; Santoru et al., 2014; Sassoè-Pognetto et al., 2007). Long-term EE-LNG treatment also decreased cerebrocortical concentrations of testosterone in intact female rats (Santorù et al., 2014), matching the lower serum testosterone levels observed in women using HC (Graham et al., 2007; Paoletti et al., 2004).

Circulating estradiol levels are also altered by HC in female Sprague-Dawley rats. LNG administration (125 µg) for five days decreased serum estradiol levels, compared to controls in proestrus (naturally high estradiol), but not in metestrus (naturally low estradiol), and such alteration normalized within five days from drug suspension, or following treatment with estrogen receptors (ER α and ER β) agonists (Graham and Milad, 2013). Serum estradiol levels were also reduced following three-weeks administration of EE (30 µg), LNG (60 µg), or their combination, compared to control rats in the early diestrus/metestrus phase of the ovarian cycle, when estradiol levels are naturally low compared to the proestrus phase; however, lower doses of EE (10 µg), LNG (20 µg), or their combination did not alter estradiol levels, suggesting that higher doses of EE and LNG may be required to inhibit the hypothalamic-pituitary-gonadal (HPG) axis in rodents (Simone et al., 2015).

The molecular mechanisms by which HC decrease neuroactive steroid levels may depend on inhibition of the HPG axis but may also include direct effects of the synthetic estrogen and progestins on enzymatic expression and activity. Indeed, LNG inhibits basal and LH-stimulated progesterone synthesis, as well as the conversion of pregnenolone to progesterone in cultured rat luteal cells, suggesting a potential direct action on 3 β -hydroxysteroid dehydrogenase (Tellería et al., 1994). Similarly, LNG inhibits 5 α -reductase activity in skin (Rabe et al., 2000). Whether HC alter the expression and activity of neurosteroidogenic enzymes in the brain is still undetermined; however, our observation that long-term EE-LNG treatment also reduces cerebrocortical concentrations of pregnenolone, progesterone and allopregnanolone in ovariectomized rats (Follesa et al., 2002), leads us to speculate that HC may have a direct effect on brain neurosteroidogenesis, independent from peripheral synthesis.

In summary, the HC-induced decrease in estradiol, progesterone and allopregnanolone levels may affect normal brain function and might contribute to some of the side effects of HC at the central nervous system level, given that these neuroactive hormones exert numerous beneficial effects in the brain, including mood enhancing effects, neuroprotection, and modulation of neuronal plasticity and cognition.

2.1. Hormonal contraceptives and stress-related hormone levels

In addition to the above-mentioned changes in estradiol, progesterone and allopregnanolone, HC also target the hypothalamic-pituitary-adrenal (HPA) axis and increase basal circulating cortisol in women (Kirschbaum et al., 1999; Paoletti et al., 2004; Wiegratz et al., 2003). However, their effects on free salivary and plasma cortisol are contradictory and inconclusive (Boisseau et al., 2013; Kirschbaum et al., 1999; Reynolds et al., 2013), perhaps due to genotype (Hamstra et al., 2015). HC users also show a blunted cortisol response to psychosocial or physical stress and to HPA pharmacological challenges with naltrexone, or adrenocorticotrophic hormone (ACTH) (Kirschbaum et al., 1999; Kirschbaum et al., 1995;

Roche et al., 2013), as well as blunted plasma ACTH content in response to corticotropin releasing hormone challenge (Jacobs et al., 1989), suggestive of reduced sensitivity to stress. Interestingly, similar responses were also observed in adult female cynomolgus monkeys that have a reproductive physiology similar to the women's one (Henderson and Shively, 2004). Likewise, female rats chronically treated with EE-LNG also showed increased basal corticosterone levels and a blunted corticosterone response to acute restraint stress (Porcu et al., 2019).

Given that EE, but not progestins, induces a dose-dependent increase in cortisol binding globulin (CBG) levels (Wiegratz et al., 2003), this mechanism may likely account for HC' effects on basal and stress-induced cortisol levels. Indeed, HC users with higher CBG content have blunted ACTH and cortisol responses to psychosocial stress, compared to users with lower CBG content (Kumsta et al., 2007). Moreover, women using a LNG-releasing intrauterine device show an increased salivary cortisol response to stress (Aleknaviciute et al., 2017), further supporting the hypothesis that effects of HC on cortisol responses may depend on the estrogenic component and its ability to alter CBG levels.

On the other hand, HPA homeostasis is also regulated by the neuroactive steroid allopregnanolone acting on hypothalamic GABAergic neurons (Biggio et al., 2014; Gunn et al., 2015), and we hypothesized that the decrease in brain and plasma allopregnanolone levels, induced by long-term EE-LNG treatment in female rats, might contribute to the altered basal and stress-stimulated corticosterone responses, thus leading to reduced sensitivity to effects of stress. However, acute restraint stress increased plasma allopregnanolone levels in controls but not EE-LNG-treated rats, suggesting that EE-LNG treatment prevents the allopregnanolone response to stress necessary to restore HPA axis homeostasis (Porcu et al., 2019). Thus, long-term treatment with HC may increase vulnerability to affective disorders via reduced sensitivity of the HPA axis to the effects of stress, a condition also observed in depression (Baumeister et al., 2014).

All the above-mentioned studies have mainly examined basal or acute stress effects of HC on the HPA axis. However, studying the effects of HC in conditions of chronic stress will be of utmost importance, especially in light of challenges currently imposed worldwide by the COVID-19 pandemic, in addition to other long-term stressful events that many women may experience in their life.

3. Hormonal contraceptives alter neurotransmitters, neuropeptides, and circadian rhythms

Regulation of the HPG axis, the main target of HC, is under the control of different neurotransmitters, including γ -aminobutyric acid (GABA), glutamate, monoamines, and acetylcholine; furthermore, the hypothalamus is also the brain area where circadian clocks controlling biological rhythms are located. Likewise, steroid hormones influence the synthesis of specific neuropeptides, such as brain derived neurotrophic factor (BDNF). However, very few preclinical studies have examined HC' effects on neurotransmitters and neuropeptides (Table 1).

3.1. Neurotransmitters

HC increased GABA levels, decreased glutamate levels, and altered glutamate decarboxylase and aminobutyrate activities in rat brain, depending on the hormonal combination (Table 1) (Daabees et al., 1981; Ghazal et al., 1976). Furthermore, we showed that long-term treatment (4-6 weeks) with EE-LNG alters GABA_A receptor subunit expression in the rat cerebral cortex and hippocampus (Table 1) (Follesa et al., 2002; Porcu et al., 2012). GABA_A receptors belong to the ligand gated ion channel family and are formed by five subunits, typically 2 α s, 2 β s and a γ or δ subunit; in addition to the binding site for GABA, they are positively modulated by endogenous neuroactive steroids such as allopregnanolone (Sieghart and Savić, 2018).

Long-term EE-LNG treatment (30-125 $\mu\text{g}/\text{rat}$, respectively) increased mRNA expression for the $\gamma 2\text{L}$ and $\gamma 2\text{S}$ isoforms in the rat cerebral cortex and such alteration normalized in two weeks from drug discontinuation (Follesa et al., 2002). Likewise, the abundance of the $\gamma 2$ protein increased in both cerebral cortex and hippocampus of EE-LNG-treated rats, compared to vehicle-treated rats (Follesa et al., 2002; Porcu et al., 2012). However, cerebrocortical and hippocampal mRNA expression and proteins for $\alpha 1$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 1$, $\beta 2$, and $\beta 3$ subunits were not affected by long-term EE-LNG treatment (Follesa et al., 2002; Porcu et al., 2012), thus suggesting a selective effect of EE-LNG on the $\gamma 2$ subunit. Further, the scaffold protein gephyrin was also not affected by EE-LNG treatment (Sassoè-Pognetto et al., 2007).

GABA_A receptor subunit expression is influenced by fluctuations in allopregnanolone content that occur in physiological conditions like puberty (Shen et al., 2007), ovarian cycle (Lovick et al., 2005; Maguire et al., 2005), pregnancy and lactation (Concas et al., 1998; Maguire and Mody, 2008; Sanna et al., 2009), or following pharmacological treatments (Calza et al., 2010; Follesa et al., 2001; Locci et al., 2017; Modol et al., 2014; Shen et al., 2005; Smith et al., 1998). Thus, the marked decrease in cerebrocortical and hippocampal levels of allopregnanolone, induced by long-term treatment with EE-LNG might contribute to the observed changes in GABA_A receptor $\gamma 2$ subunit expression (Follesa et al., 2002; Porcu et al., 2012; Sassoè-Pognetto et al., 2007). Intriguingly, $\gamma 2$ subunit expression can change in response to other conditions associated to fluctuations in allopregnanolone content. For instance, during pregnancy elevated allopregnanolone levels are paralleled by a decrease in $\gamma 2$ subunit mRNA and protein in rat cerebral cortex and hippocampus, a condition prevented by treatment with the 5α -reductase inhibitor finasteride that decreases brain allopregnanolone levels (Concas et al., 1998). Likewise, $\gamma 2$ subunit mRNA and protein increase immediately before parturition when the brain concentrations of allopregnanolone abruptly decline (Concas et al., 1998); similarly, the abundance of $\gamma 2$ subunit mRNA in the posterior paraventricular nucleus remains elevated during lactation, when brain concentrations of neuroactive steroids in rats continue to be low (Fénelon and Herbison, 1996). Thus,

the increased expression of the GABA_A receptor γ 2 subunit, induced by long-term EE-LNG treatment, might be related to the decrease in brain allopregnanolone levels. However, this assumption is not supported by data showing that only long-term treatment with the progestin LNG alone alters GABA_A receptor subunit expression, while EE alone does not, despite both treatments are equally effective in reducing brain allopregnanolone levels (Porcu et al., 2012). Hence, the HC-induced changes in γ 2 subunit expression might be attributed to LNG, rather than to the low allopregnanolone content. LNG displays a potent progesterone-like activity, but it also binds to androgen receptors (Cabeza et al., 1995; Lemus et al., 1992) and to intracellular mineralocorticoid receptors (Sitruk-Ware and Nath, 2010); moreover, its A-ring reduced derivatives, 3 α ,5 α - and 3 α ,5 β -LNG, show enhanced binding affinity for androgenic receptors compared to LNG (Lemus et al., 1992). Thus, LNG or its metabolites might alter γ 2 subunit expression through androgen receptors; indeed, chronic exposure to androgenic steroids also regulates GABA_A receptor expression (McIntyre et al., 2002). Nonetheless, LNG might alter GABA_A receptor subunit expression through its 3 α ,5 α - and 3 α ,5 β -reduced metabolites directly interacting with this receptor system, although a direct action of these LNG metabolites on the GABA_A receptor has not been proven yet. To summarize, alterations in GABA_A receptor expression induced by HC might contribute to some adverse effects sometimes experienced by women, given that the GABAergic transmission is involved in several psychophysiological states, such as anxiety, depression, sleep, cognitive function, seizures, and sexual behavior.

Very few studies, mostly conducted a while ago and thus using older formulations, have examined the effects of HC on other neurotransmitters' systems (Table 1). Acetylcholine and choline brain levels, as well as choline acetyltransferase activity did not change in both mice and rats following chronic HC treatment for 12 or 30 days (Daabees et al., 1981; Ladinsky et al., 1976). By contrast, HC decreased dopamine levels in the striatum of rats and mice (Jori and Dolfini, 1976). Moreover, a decrease in tyrosine hydroxylase expression was also observed in the locus coeruleus following chronic

administration of low EE-LNG doses (10-20 μg), while higher doses (30-60 μg) increased tyrosine hydroxylase mRNA but not protein levels (Simone et al., 2015). Likewise, monoamine oxidase activity was reduced by treatment with estradiol in combination with norgestrel (Marchi and Cugurra, 1974). Finally, serotonin and its precursor tryptophan were increased in rat brain following acute administration of medroxyprogesterone acetate, as well as chronic treatment with EE in combination with different progestins (Baker et al., 1977; Daabees et al., 1981); however, administration of norethisterone acetate alone failed to alter these neurotransmitters in mice (Baker et al., 1977).

3.2. Neuropeptides

Chronic treatment with EE-LNG decreased hippocampal BDNF mRNA and protein in female rats (Simone et al., 2015), an effect most likely associated to the HC-induced reduction in brain and plasma levels of neuroactive steroid hormones. In fact, BDNF expression is strongly influenced by estradiol through a direct control of an estrogen response element present in the BDNF gene (Sohrabji et al., 1995). Furthermore, both progesterone and allopregnanolone increase BDNF expression in various brain regions (Almeida et al., 2019; Naert et al., 2007). Indeed, hippocampal BDNF expression changes across the rat estrus cycle (Scharfman et al., 2003), and serum BDNF levels in women fluctuate over the menstrual cycle, being highest during the luteal phase, although such fluctuations were absent in women taking HC (Pluchino et al., 2009).

Low EE doses (10 μg), alone or in combination with LNG, increased galanin peptide in the rat locus coeruleus, while higher EE doses (30 μg) were ineffective, despite increasing galanin mRNA (Simone et al., 2015). Given that galanin is a stress-inducible neuropeptide and cotransmitter in serotonergic and noradrenergic neurons, potentially involved in stress-related disorders (Juhász et al., 2014), authors hypothesized that the EE-induced increase in galanin might contribute to changes in anxiety and cognition through inhibition of the noradrenergic transmission (Simone et al., 2015).

3.3. Biological rhythms

Biological rhythms regulate several physiological and behavioral functions and are controlled by the suprachiasmatic nucleus of the hypothalamus (Neumann et al., 2019). Short-term (8 days) administration of EE-LNG (30-30 µg/day) to adolescent female Wistar rats, from postnatal day 50 to 58, prevented the peak fecal estradiol level that occurs during the estrus cycle. Following HC exposure circadian rhythm power was reduced and failed to correlate with fecal estradiol levels; furthermore, HC disrupted the 4-day temperature rhythms and reduced core body temperature. Importantly, all these effects persisted after drug discontinuation and into early adulthood (Grant et al., 2021). Despite the artificial laboratory conditions, including ovariectomy and subsequent hormone replacement, this study is the first to show an effect of HC on biological rhythms that may have long-term consequences even after treatment cessation.

4. Psychobehavioral effects of hormonal contraceptives

4.1. Emotional state

Emotional disorders such as depression and anxiety are more frequent in women than men, and the hormonal fluctuations associated with the ovarian cycle have been suggested to contribute to the increased vulnerability to mood disorders and to the greatest risk of developing a depressive episode following puberty (Hantsoo and Epperson, 2017; Kuehner, 2017). Studies examining the effects of HC on mental health in women have yielded mixed results, with improvement (Keyes et al., 2013; Toffol et al., 2012), no change (Cheslack-Postava et al., 2015; Lundin et al., 2017; Morssinkhof et al., 2021; Rapkin et al., 2006b; Schaffir et al., 2016; Scheuringer et al., 2020), or worsening (Deci et al., 1992; Oinonen and Mazmanian, 2002; Skovlund et al., 2016; Sundstrom Poromaa and Segebladh, 2012) in symptoms of

depression and anxiety. Young age is one of the factors that may account for these discrepancies. Evidence from several recent studies reports that adolescents using HC are more likely to experience depressive symptoms and a first diagnosis of depression, to use psychotropic drugs and to have a higher relative risk for suicide (Anderl et al., 2022; Anderl et al., 2020; de Wit et al., 2020; Edwards et al., 2020; Gregory et al., 2018; Skovlund et al., 2018; Skovlund et al., 2016; Zettermark et al., 2018). Within HC users, adolescents show a greater blunted cortisol response to the Trier social stress test compared to adults, which has been hypothesized to contribute to their increased vulnerability to depression (Sharma et al., 2020b). Further, a genetic predisposition to mood disorders may also contribute to HC effects on mental health. HC users who carry the mineralocorticoid receptor haplotype 1 or 3 showed a higher rate of depressive symptoms, while those carrying the haplotype 2 appear to be protected against the adverse effects on mood (Hamstra et al., 2015), suggesting that HC may negatively influence emotional states in those women who may be genetically predisposed to mood disorders (Hamstra et al., 2017; Hamstra et al., 2016; Hamstra et al., 2015; Rapkin et al., 2006b; Segebladh et al., 2009).

Endogenous steroid hormones modulate emotional state in humans. While, the anxiolytic effects of estradiol are controversial (Nouri et al., 2022), allopregnanolone concentrations are decreased in plasma and cerebrospinal fluid of depressed patients and can be normalized by antidepressant treatment (Uzunova et al., 1998), strongly suggesting that allopregnanolone may be involved in the etiology of depression (Boero et al., 2020; Bäckström et al., 2014). Endogenous steroid hormones also modulate emotional behavior in animal models (Hwang et al., 2020; Porcu et al., 2016) and we thus hypothesized that the decrease in the concentrations of estradiol, progesterone, and its neuroactive metabolite allopregnanolone induced by long-term administration of HC would affect anxiety- and depressive-like behavior in female rats.

4.1.1. Anxiety-like behavior

The effects of HCs on anxiety-like behavior have been examined in female rats. Long-term treatment with EE-LNG (30-125 $\mu\text{g}/\text{rat}$, respectively) induced an anxiety-like behavior in the elevated plus maze test (Follesa et al., 2002), and we hypothesized that such effect might be the consequence of decreased brain allopregnanolone content induced by HC, given that this neuroactive steroid exerts anxiolytic properties (Bitran et al., 1991). However, long-term treatment with EE alone failed to alter anxiety-like behavior, while LNG alone increased such behavior despite both treatments reduced brain allopregnanolone levels to a similar extent (Porcu et al., 2012). We thus hypothesized that the EE-LNG-induced anxiety-like behavior was likely due to LNG or its metabolites. LNG binds to progesterone receptors, but it also has a potent activity via androgen receptors. Moreover, it can be A-ring reduced to form 5α -LNG and $3\alpha,5\alpha$ -LNG, and to a minor level $3\beta,5\alpha$ -LNG (Lemus et al., 1992). Indeed, acute administration of $3\beta,5\alpha$ -LNG and $3\alpha,5\alpha$ -norethisterone exerted an anxiolytic effect in ovariectomized Wistar rats, while acute administration of LNG or norethisterone did not alter anxiety-like behavior in the burying behavior test (Picazo et al., 1998). Likewise, long-term LNG administration induced anxiety, mood disorders, and sleep problems in otherwise healthy women without a prior record of these events (Slattery et al., 2018; Wagner and Berenson, 1994).

By contrast, chronic administration of low EE and LNG doses (10 and 20 μg , respectively) exerted an anxiolytic effect in the elevated plus maze test and the shock-probe defensive burying test; however, higher EE-LNG doses (30-60 μg) did not alter anxiety-like behavior in the elevated plus maze test and EE alone at the higher dose (30 μg) increased freezing in the shock-probe defensive burying test (Simone et al., 2015). The EE-LNG-induced changes in anxiety-like behavior correlated with tyrosine hydroxylase expression in the locus coeruleus, suggesting an involvement of the noradrenergic transmission in the HC-mediated anxiety-like behavior in rats (Simone et al., 2015). Thus, HC may modulate anxiety-like behavior through multiple different mechanisms; future studies in rodents are necessary to elucidate these mechanisms to better target potential side effects of these drugs.

4.1.2. Depression-like behaviors

We further hypothesized that the reduction in brain allopregnanolone content induced by long-term EE-LNG treatment might affect depressive-like behavior in female rats. However, we found that such treatment did not alter sucrose intake in the sucrose preference test (Santoru et al., 2014) that assesses anhedonia, a core symptom of depression (Willner, 1997). We also performed the forced swim test, and we observed a reduction in immobility time in EE-LNG-treated rats compared to vehicle-treated rats (Santoru et al., 2014), indicative of an antidepressant effect of EE-LNG, according to the original interpretation by Porsolt (Porsolt et al., 1977). However, this behavioral paradigm may not be appropriate to detect antidepressant-like behavior in the presence of stress and anxiety, and it has been suggested that immobility in the forced swim test may represent a switch from active to passive behavior in order to cope with an acute stressor (Estanislau et al., 2011; Molendijk and de Kloet, 2015). Thus, given that HC blunt the HPA axis response to acute stress in both women (Kirschbaum et al., 1999; Kirschbaum et al., 1995) and female rats (Porcu et al., 2019), the reduction in immobility induced by long-term EE-LNG-treatment might be due to an inability to cope with the acute swim stress, rather than to a change in depressive-like behavior.

4.1.3. Fear extinction

Fear conditioning and extinction is a valuable experimental paradigm to study the mechanisms underlying emotional learning; this behavioral model is modulated by hormone levels and can be used in different species (Maeng and Milad, 2015). Women using HC have impaired fear extinction, measured as an increase in recovery of fear, compared to free-cycling women in the high estrogen phase, suggesting that fear responses persist for a longer time in HC users (Graham and Milad, 2013). Similarly, impaired extinction recall was observed in female rats following LNG administration. In both women and

female rats, HC did not alter acquisition of fear and extinction (Graham and Milad, 2013). The decrease in estradiol levels induced by HC or by LNG alone might contribute to the impairment in fear extinction. In fact, ER α or ER β agonist administered to LNG-treated rats reduced freezing during extinction recall. Moreover, estradiol enhances the consolidation of extinction in naturally cycling women, as its administration avoided recovery of fear during extinction recall (Graham and Milad, 2013). In addition, the reduction in progesterone and allopregnanolone levels induced by long-term HC exposure may also contribute to the impaired extinction recall, given that these neuroactive hormones also contribute to fear extinction (Milad et al., 2009; Pibiri et al., 2008).

4.2. Social behavior

Rodents, like humans, are social species and a detailed observation of their behavior in a social context can provide information on their social abilities and social status in terms of being dominant or remissive towards a conspecific. We evaluated social interaction in the resident-intruder test, where agonistic behaviors (follow the intruder, dominant postures, and attacks) displayed by the resident rat towards an intruder are scored to estimate dominance and aggressive social interaction. Long-term EE-LNG treatment alters social interaction in adult female rats; in fact, such treatment decreased both frequency and duration of dominant and agonistic behaviors suggesting that EE-LNG-treated rats were less dominant compared to vehicle-treated rats (Santoru et al., 2014). Similarly, in cynomolgus monkeys HC increased frequency of contact aggressions received and relaxed vigilance (Henderson and Shively, 2004). Social and aggressive interactions are mediated by steroid hormones in both animals and humans (Soma et al., 2008). While testosterone mediates aggressive behavior and attacks in males (Koolhaas et al., 1980), estradiol and progesterone fluctuations during the ovarian cycle influence aggression in female rats, a behavior blunted by ovariectomy (Ho et al., 2001). Thus, multiple neuroactive steroids may be influencing agonistic behavior in EE-LNG-treated female rats. In fact, long-term EE-LNG

treatment decreases brain and plasma progesterone levels (Follesa et al., 2002; Porcu et al., 2012), as well as cerebrocortical testosterone levels (Santoru et al., 2014), which might contribute to the decrease in social dominance observed in female rats, given that testosterone levels are associated with aggressive behavior and social dominance in both animals and humans (Archer, 2006; Van de Poll et al., 1988). Allopregnanolone also increases aggressive behaviors in male mice subjected to the resident-intruder test (Fish et al., 2001); thus, the decrease in dominant and agonistic behaviors induced by long-term EE-LNG treatment in female rats might be related to the blunted allopregnanolone content following such treatment (Follesa et al., 2002; Porcu et al., 2012; Santoru et al., 2014). However, allopregnanolone is less likely to be involved; in fact, a different outcome in the resident-intruder test has been reported in other experimental conditions of reduced brain and plasma allopregnanolone levels. For instance, a single exposure to estradiol on the day of birth that induces defeminization in adult female rodents and persistently decreases brain and plasma allopregnanolone levels (Calza et al., 2010; Locci et al., 2017), increased agonistic behavior in adult female rats (Berretti et al., 2014). Likewise, male rats and mice subjected to juvenile social isolation display an aggressive behavior along with marked reductions in brain allopregnanolone content (Pinna et al., 2003; Serra et al., 2007).

Long-term EE-LNG treatment further decreased social investigation in the resident-intruder test. In particular, body and anogenital investigation were reduced in EE-LNG-treated female rats, compared to vehicle-treated female rats (Santoru et al., 2014). While the reduced anogenital investigation might be related to a decrease in sexual interest toward the intruder, as this is an appetitive behavior aimed to establish, maintain and promote sexual interaction (Everitt, 1990), the significance of the reduced social investigation is unclear. Interestingly, HC use negatively influences affective empathy towards strangers (Kimmig et al., 2021), and lower levels of prosocial behavior and emotional empathy were also reported in women using HC, compared to non-HC users, and such effect appeared to be associated with the lower progesterone levels in HC users (Strojny et al., 2021). Moreover, both social and sexual stimuli are

influenced by oxytocin. To the best of our knowledge, the effects of HC on the oxytocinergic system have not yet been investigated in animal models. In women, oxytocin levels fluctuate across the menstrual cycle, being lower during the luteal phase, while no such fluctuations were observed in women taking HC (Salonia et al., 2005), although other studies reported an increase in plasma oxytocin in women under HC treatment (Silber et al., 1987; Stock et al., 1994). Moreover, HC alter oxytocin-mediated reward sensitivity to social and sexual stimuli in women (Scheele et al., 2016), suggesting that they may also influence social and sexual behavior through the oxytocinergic system.

4.3. Sexual behavior

HCs have been reported to influence women's sexual well-being although evidence remains controversial (Both et al., 2019; Caruso et al., 2022) and may depend on the form of HC used (Guida et al., 2017). An improvement, likely due to the increased feeling of security and self-confidence (Buggio et al., 2022; Guida et al., 2005; Strufaldi et al., 2010), no change (Pastor et al., 2013), and a decrease in libido, sexual arousal, and frequency of sexual activities (Battaglia et al., 2012; Caruso et al., 2004; Graham et al., 2007; Graham et al., 1995; Malmborg et al., 2020; Smith et al., 2014; Wallwiener et al., 2010) have been reported; indeed adverse changes in sexuality and mood were the strongest predictors for HC termination in the first six months of use (Sanders et al., 2001).

Estrogen and progesterone synergistically promote sexual behavior in animals (Gilman and Hitt, 1978); likewise, allopregnanolone also controls this behavior by increasing proceptive and receptive behaviors in female rats (Frye et al., 1998). Therefore, the decrease in neuroactive steroids induced by HC may contribute to sexual well-being in both women and animals. In line with this hypothesis, we reported that long-term EE-LNG treatment significantly decreased the frequency of proceptive behaviors (ear wiggling, hops and darts) displayed by receptive females in order to attract and facilitate the male mounts; receptive behaviors (lordosis) were also reduced, though not significantly (Santoru et

al., 2014). Likewise, in non-human primates HC induce a reduction in the ability to attract mates and in the cyclic increase in female anogenital swelling, indices of decreased proceptive behaviors (Baum, 1983; Guy et al., 2008; Nadler et al., 1992). These preclinical findings support evidence from a recent meta-analysis of 12 clinical studies involving 9427 participants reporting that sexual desire can be significantly compromised by HC use, although other measures of sexual dysfunction in women are not affected (Huang et al., 2020).

Animal models allow us to test the involvement of each neuroactive steroid in regulation of sexual behavior. We thus investigated whether administration of estradiol and/or progesterone could reinstate sexual behavior in EE-LNG-treated rats. Estradiol administration *per se* did not alter lordosis and proceptive behaviors; by contrast, progesterone, alone or in combination with estradiol, restored such behaviors, suggesting that the pronounced decrease in brain and peripheral levels of progesterone, induced by long-term EE-LNG treatment in female rats, contributes to the reduced sexual behavior (Santoru et al., 2014). Moreover, the effects of progesterone on sexual behavior appear to be mediated by its neuroactive metabolite allopregnanolone. Indeed, brain allopregnanolone content is increased when rats are maximally receptive or following mating, and systemic administration or intracerebral infusion of this neuroactive steroid promotes mating in ovariectomized rats (Frye, 2001; Frye and Rhodes, 2006; Glaser et al., 1985; Henderson, 2007). On the contrary, inhibition of allopregnanolone biosynthetic enzymes diminishes sexual behavior in female rats (Frye and Vongher, 2001). In agreement with these results, we observed that administration of finasteride (a 5α -reductase inhibitor that blocks the conversion of progesterone to allopregnanolone), which *per se* did not alter receptive and proceptive behaviors, prevented reinstatement of proceptive behaviors following progesterone administration to EE-LNG-treated rats, suggesting that the decrease in proceptive behaviors induced by HC treatment in female rats is related to the decrease in the brain allopregnanolone levels (Santoru et al., 2014).

Sexual behavior is also influenced by testosterone in both animals and humans (Frye, 2001; Giraldo et al., 2004; Stuckey, 2008), and HC decrease serum testosterone levels in women (Graham et al., 2007; Paoletti et al., 2004), as well as its cerebrocortical concentrations in female rats (Santoru et al., 2014). Nevertheless, administration of progesterone, finasteride or their combination did not alter cerebrocortical testosterone levels in EE-LNG-treated rats, suggesting that the decrease in proceptive behaviors induced by long-term EE-LNG treatment is not related to testosterone concentrations (Santoru et al., 2014). Overall, these results further support the involvement of allopregnanolone in regulation of sexual behavior in rodents and in the HC-induced alterations, suggesting that allopregnanolone might contribute to negative changes in sexual well-being experienced by some women using HC.

4.4. Learning and memory

It is well accepted that neuroactive steroid hormones regulate learning and memory. Several studies have examined the effects of HC on cognitive performance in women leading to mixed results. Specifically, HC can cause amelioration (Gurvich et al., 2020; Plamberger et al., 2021; Rosenberg and Park, 2002), no difference (Gogos, 2013; Gravelsins et al., 2021; Islam et al., 2008; Mihalik et al., 2009; Mordecai et al., 2008; Rosenberg and Park, 2002), or worsening (Bradshaw et al., 2020; Griksiene et al., 2018; Griksiene and Ruksenas, 2011) in cognitive abilities, compared to naturally cycling women. Reasons for such discrepancies may include different cognitive domains analyzed (verbal fluency, visuospatial abilities, mental rotation task, etc.), as well as different duration of treatment and doses and type of progestin administered. Few examples include different outcomes in mental rotation performance (i.e. the spatial cognitive ability to mentally detect objects with different spatial orientation) depending on the type of progestin (Griksiene et al., 2018; Griksiene and Ruksenas, 2011; Wharton et al., 2008), or the different dose of EE (Beltz et al., 2015) used. Moreover, HCs can induce

either improvement (Gogos et al., 2014; Mordecai et al., 2008), or no difference (Gordon and Lee, 1993; Islam et al., 2008; Wharton et al., 2008) in verbal memory, a traditionally female-favoring domain. By contrast, visuospatial ability, a male-favoring domain, did not change between HC users and non-users (Gogos et al., 2014; Gordon and Lee, 1993; Islam et al., 2008; Mordecai et al., 2008), except for one study that reported opposite effects depending on the kind of progestin (androgenic or anti-androgenic) used (Wharton et al., 2008).

Very few studies have examined learning and memory in animals following HC exposure. Long-term treatment with EE-LNG (30-125 μg) did not alter spatial learning and memory in female Sprague-Dawley rats that underwent the Morris water maze test (Santorù et al., 2014). The same treatment also did not alter behavioral flexibility in the Morris water maze test (Boi et al., submitted). Likewise, in the same rat strain chronic EE-LNG treatment (30-60 μg) did not alter visuospatial memory in the novel object recognition and novel context recognition tests (Simone et al., 2015). However, lower doses of EE (10 μg), LNG (20 μg), and their combination impaired recognition memory in the novel object recognition test, while the higher EE dose (30 μg) improved preference for the novel object compared to vehicle-treated rats (Simone et al., 2015). By contrast, in the novel context recognition test none of the EE and LNG treatments or their combinations affected memory, except for administration of LNG (20 μg) that improved recognition memory compared to vehicle-treated rats (Simone et al., 2015).

Given that HC treatment blunts levels of estradiol, progesterone and allopregnanolone that are known to affect learning and memory performance (Chesler and Juraska, 2000; Johansson et al., 2002), these results were unexpected. However, they may depend upon the experimental conditions and the specific memory domains examined. We cannot rule out the possibility that HC may affect cognition in different experimental settings (species/strain, doses, duration of treatment, behavioral test, etc.) used. For instance, chronic EE administration to adult ovariectomized rats decreased working memory in the water radial arm maze, with no change in spatial reference memory in the Morris water maze

(Mennenga et al., 2015). However, we believe these results, albeit relevant to the understanding of estrogen effects on cognitive performance, lack translational value because women taking HC for contraceptive purposes have an intact HPG axis.

By contrast, another preclinical study examined the effects of 4-months exposure to HC in a rodent model of menopause in which adult intact Fisher-344 female rats received medroxyprogesterone acetate from months 4 to 8, were ovariectomized on month 10, and tested on month 12, following an additional treatment with either vehicle or medroxyprogesterone acetate (to mimic hormone replacement therapy). Such treatment impaired working memory in the water radial arm maze but did not change spatial reference memory in the Morris water maze (Braden et al., 2011). This finding may be relevant for those women currently undergoing hormone replacement therapy in menopause, who are more likely to have used HC for contraceptive purposes, compared to older generations of women for which HC were not yet available.

The molecular mechanisms beyond the HC-induced changes in cognitive performance are still unknown. Simone et al., showed that impaired memory in the novel object recognition test was associated to reduced hippocampal BDNF mRNA expression, the neurotrophin implicated in learning and memory. Further, such decrease was also positively correlated with tyrosine hydroxylase mRNA expression in the locus coeruleus, suggesting the involvement of noradrenergic transmission on BDNF expression and possibly on HC-induced cognitive performance (Simone et al., 2015).

4.5 Reward

Steroid hormones affect reward in both animals and humans. Administration of estradiol or progesterone modulates reward in rodents (Anker and Carroll, 2010; Yoest et al., 2014); likewise, allopregnanolone has rewarding properties (Finn et al., 1997; Fish et al., 2014; Sinnott et al., 2002), influencing alcohol and cocaine intake (Anker and Carroll, 2010; Morrow et al., 2006). Reward reactivity

in women is affected by hormonal fluctuations across the menstrual cycle (Bayer et al., 2013; Dreher et al., 2007), and by hormone therapy in perimenopausal women (Thomas et al., 2014). Thus, HC likely affect reward, although only few studies have examined this aspect. HC users showed increased sensitivity to monetary reward (Bonenberger et al., 2013), but also a reduction in the oxytocin-induced reward associated to the partner's attractiveness (Scheele et al., 2016). Further, HC use differentially modulated smoking satisfaction across the menstrual cycle, as well as affect after smoking abstinence (Hinderaker et al., 2015). EE was recently shown to modulate nicotine self-administration in ovariectomized Long-Evans rats (Maher et al., 2021); however, this model lacks translational value to study the effects of HC, given that these drugs are taken by young premenopausal women. Thus, future studies in animal models of reward-related behavior are needed to examine putative effects of long-term HC exposure on reward.

5. Conclusions and future directions

We reported evidence that HC affect brain function through many effects on neuroactive steroid hormones, neurotransmission, neuropeptides, and related psychobehavioral impact (Table 1). Preclinical studies using animal models to investigate HC's effects on brain function and behavior are limited and we must consider several methodological differences, including species, strains, age, housing environment, doses and duration of treatment used, when interpreting and translating current results to the clinic. Nonetheless, animal models remain a valuable tool to investigate the cellular and molecular mechanisms involved in HC's action on brain function, given that they allow for the direct measurement of several neuromodulators in brain tissue. In fact, other aspects remain to be explored.

An important one pertains to HC effects on the adolescent brain. HC are frequently used by adolescents for therapeutic and contraceptive purposes and the number of young girls who use HC has been steadily increasing over the last decade (United Nations, 2019). The adolescent brain is not fully

mature yet, and its maturation is influenced by the surge in steroid hormones levels that occurs at puberty. Therefore, it is quite relevant to understand the effects of HC during adolescence especially whether the depletion in steroid hormones induced by use of these drug can have long-term consequence on the developing brain. Indeed, the adolescent brain may respond differently than the adult brain to the psychobehavioral effects of HC (Cahill, 2018), and clinical studies suggest that HC use during adolescence blunts the response to stress, alters brain working memory processing for negative stimuli and resting state functional connectivity (Sharma et al., 2020a; Sharma et al., 2020b), conditions that may contribute to the increased vulnerability to mood disorders (Anderl et al., 2022; Anderl et al., 2020; de Wit et al., 2020; Gregory et al., 2018; Skovlund et al., 2016; Zettermark et al., 2018). One challenging aspect in studying the effects of HC in adolescence using animal models is that adolescence in rodents has a short timeframe (approximately two weeks from postnatal day 28 to 42). Estradiol and progesterone levels start to rise at postnatal day 40 in female rats, but reach stable levels comparable to the adult ones only at postnatal day 48; likewise, the estrus cycle stabilizes by postnatal day 75 (Vetter-O'Hagen and Spear, 2012). Therefore, treatment with HC before that timeframe is likely to disrupt the normal development of the HPG axis in adolescent rodents, with long-term consequences for brain development. In addition, approximately $\frac{1}{4}$ of sexually active adolescents reported using emergency contraception, which consists of a single higher dose of a progestin, usually levonorgestrel (Williams et al., 2021). The consequences of such intervention for brain function are still understudied and might be particularly critical during adolescence when the brain is still under development and highly responsive to steroid hormones.

Another important aspect is the reversibility of HC effects on neurotransmission and behavior after treatment discontinuation. We showed that neuroactive steroid levels and expression of the $\gamma 2$ subunit of the GABA_A receptor normalize two weeks after drug discontinuation (Follesa et al., 2002), but not all the behavioral effects induced by long-term HC treatment are related to the decrease in the

above-mentioned parameters; thus, whether HC may induce any persistent effects on behavior or other molecular markers remains to be clarified.

Emerging evidence in women using HC points to the importance of genotype in the susceptibility to certain neuropsychiatric symptoms (i.e., mineralocorticoid receptor haplotypes, catechol-o-methyltransferase, (Gravelsins et al., 2021; Hamstra et al., 2017; Hamstra et al., 2016; Hamstra et al., 2015)). Animal models allow for manipulation of targeted genes to better understand the genetic component involved in certain HC-mediated behavioral phenotypes. Furthermore, clinical advances driven by progress in genetics and by neuroimaging will facilitate the development of new useful animal models that can combine small-animal imaging techniques, optogenetics and measurement of high-throughput central and peripheral biomarkers, to investigate HC's effects on brain function.

Animal models are indispensable tools for research on the neurobiological mechanisms underlying the effects of HC on brain function and behavior that may be helpful to shed light on some of the side-effects of HC on the central nervous system that affect women's well-being.

Acknowledgements

This work was supported by the Banco di Sardegna Foundation (Grant 2012.0255), and the University of Cagliari (Premialità 2012) to A.C., and by Fondazione di Sardegna (Grants 2019.1440 and 2021.0504) to PP.

References

- Aleknaviciute, J., Tulen, J. H. M., De Rijke, Y. B., Bouwkamp, C. G., van der Kroeg, M., Timmermans, M., Wester, V. L., Bergink, V., Hoogendijk, W. J. G., Tiemeier, H., van Rossum, E. F. C., Kooiman, C. G., Kushner, S. A., 2017. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. *Psychoneuroendocrinology* 80, 39-45.
- Almeida, F. B., Gomez, R., Barros, H. M. T., Nin, M. S., 2019. Hemisphere-dependent changes in mRNA expression of GABA. *Neuroscience* 397, 56-66.
- Anderl, C., de Wit, A. E., Giltay, E. J., Oldehinkel, A. J., Chen, F. S., 2022. Association between adolescent oral contraceptive use and future major depressive disorder: a prospective cohort study. *J Child Psychol Psychiatry* 63, 333-341.
- Anderl, C., Li, G., Chen, F. S., 2020. Oral contraceptive use in adolescence predicts lasting vulnerability to depression in adulthood. *J Child Psychol Psychiatry* 61, 148-156.
- Anker, J. J., Carroll, M. E., 2010. The role of progestins in the behavioral effects of cocaine and other drugs of abuse: human and animal research. *Neurosci Biobehav Rev* 35, 315-333.
- Apter, D., Zimmerman, Y., Beekman, L., Mawet, M., Maillard, C., Foidart, J. M., Coelingh Bennink, H. J. T., 2017. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. *Eur J Contracept Reprod Health Care* 22, 260-267.
- Archer, J., 2006. Testosterone and human aggression: an evaluation of the challenge hypothesis. *Neurosci Biobehav Rev* 30, 319-345.
- Baker, J. M., Bond, S. W., Handley, S. L., 1977. Effects of long-term treatment with contraceptive steroids on plasma and brain tryptophan, brain 5-hydroxytryptamine, and locomotor activity in female mice [proceedings]. *Br J Pharmacol* 59, 531P-532P.
- Battaglia, C., Battaglia, B., Mancini, F., Busacchi, P., Paganotto, M. C., Morotti, E., Venturoli, S., 2012. Sexual behavior and oral contraception: a pilot study. *J Sex Med* 9, 550-557.
- Baum, M. J., 1983. Hormonal modulation of sexuality in female primates. *Bioscience* 33, 578-582.
- Baumeister, D., Lightman, S. L., Pariante, C. M., 2014. The interface of stress and the HPA axis in behavioural phenotypes of mental illness. *Curr Top Behav Neurosci* 18, 13-24.
- Bayer, J., Bandurski, P., Sommer, T., 2013. Differential modulation of activity related to the anticipation of monetary gains and losses across the menstrual cycle. *Eur J Neurosci* 38, 3519-3526.

- Beltz, A. M., Hampson, E., Berenbaum, S. A., 2015. Oral contraceptives and cognition: A role for ethinyl estradiol. *Horm Behav* 74, 209-217.
- Berretti, R., Santoru, F., Locci, A., Sogliano, C., Calza, A., Choleris, E., Porcu, P., Concas, A., 2014. Neonatal exposure to estradiol decreases hypothalamic allopregnanolone concentrations and alters agonistic and sexual but not affective behavior in adult female rats. *Hormones and Behavior* 65, 142-153.
- Biggio, G., Pisu, M. G., Biggio, F., Serra, M., 2014. Allopregnanolone modulation of HPA axis function in the adult rat. *Psychopharmacology (Berl)* 231, 3437-3444.
- Bitran, D., Hilvers, R. J., Kellogg, C. K., 1991. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. *Brain Res* 561, 157-161.
- Bitzer, J., Rapkin, A., Soares, C. N., 2018. Managing the risks of mood symptoms with LNG-IUS: a clinical perspective. *Eur J Contracept Reprod Health Care* 23, 321-325.
- Boero, G., Porcu, P., Morrow, A. L., 2020. Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease. *Neurobiol Stress* 12, 100203.
- Boisseau, N., Enea, C., Diaz, V., Dugué, B., Corcuff, J. B., Duclos, M., 2013. Oral contraception but not menstrual cycle phase is associated with increased free cortisol levels and low hypothalamo-pituitary-adrenal axis reactivity. *J Endocrinol Invest* 36, 955-964.
- Bonenberger, M., Groschwitz, R. C., Kumpfmüller, D., Groen, G., Plener, P. L., Ablner, B., 2013. It's all about money: oral contraception alters neural reward processing. *Neuroreport* 24, 951-955.
- Both, S., Lew-Starowicz, M., Luria, M., Sartorius, G., Maseroli, E., Tripodi, F., Lowenstein, L., Nappi, R. E., Corona, G., Reisman, Y., Vignozzi, L., 2019. Hormonal contraception and female sexuality: Position statements from the European Society of Sexual Medicine (ESSM). *J Sex Med* 16, 1681-1695.
- Braden, B. B., Garcia, A. N., Mennenga, S. E., Prokai, L., Villa, S. R., Acosta, J. I., Lefort, N., Simard, A. R., Bimonte-Nelson, H. A., 2011. Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time. *Psychopharmacology (Berl)* 218, 405-418.
- Bradshaw, H. K., Mengelkoch, S., Hill, S. E., 2020. Hormonal contraceptive use predicts decreased perseverance and therefore performance on some simple and challenging cognitive tasks. *Horm Behav* 119, 104652.
- Buggio, L., Barbara, G., Facchin, F., Ghezzi, L., Dridi, D., Vercellini, P., 2022. The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature. *Gynecol Endocrinol* 38, 193-201.

- Bäckström, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., Savic, I., Strömberg, J., Timby, E., van Broekhoven, F., van Wingen, G., 2014. Allopregnanolone and mood disorders. *Prog Neurobiol* 113, 88-94.
- Böttcher, B., Radenbach, K., Wildt, L., Hinney, B., 2012. Hormonal contraception and depression: a survey of the present state of knowledge. *Arch Gynecol Obstet* 286, 231-236.
- Cabeza, M., Vilchis, F., Lemus, A. E., Díaz de León, L., Pérez-Palacios, G., 1995. Molecular interactions of levonorgestrel and its 5 alpha-reduced derivative with androgen receptors in hamster flanking organs. *Steroids* 60, 630-635.
- Cahill, L., 2018. How does hormonal contraception affect the developing human adolescent brain? *Current Opinion in Behavioral Sciences* 23, 131-135.
- Calza, A., Sogliano, C., Santoru, F., Marra, C., Angioni, M. M., Mostallino, M. C., Biggio, G., Concas, A., 2010. Neonatal exposure to estradiol in rats influences neuroactive steroid concentrations, GABAA receptor expression, and behavioral sensitivity to anxiolytic drugs. *J Neurochem* 113, 1285-1295.
- Caruso, S., Agnello, C., Intelisano, G., Farina, M., Di Mari, L., Cianci, A., 2004. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. *Contraception* 69, 237-240.
- Caruso, S., Palermo, G., Caruso, G., Rapisarda, A. M. C., 2022. How does contraceptive use affect women's sexuality? A novel look at sexual acceptability. *J Clin Med* 11.
- Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., Koenen, K. C., 2015. Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. *Arch Womens Ment Health* 18, 103-111.
- Chesler, E. J., Juraska, J. M., 2000. Acute administration of estrogen and progesterone impairs the acquisition of the spatial morris water maze in ovariectomized rats. *Horm Behav* 38, 234-242.
- Concas, A., Mostallino, M., Porcu, P., Follesa, P., Barbaccia, M., Trabucchi, M., Purdy, R., Grisenti, P., Biggio, G., 1998. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. *Proceedings of the National Academy of Sciences of the United States of America* 95, 13284-13289.
- Daabees, T. T., El-Din, M. M., Zeitoun, R., Makar, A. B., 1981. Injectable and oral contraceptive steroids in relation to some neurotransmitters in the rat brain. *Biochem Pharmacol* 30, 1581-1585.
- De Bondt, T., Van Hecke, W., Veraart, J., Leemans, A., Sijbers, J., Sunaert, S., Jacquemyn, Y., Parizel, P. M., 2013. Does the use of hormonal contraceptives cause microstructural changes in cerebral white matter? Preliminary results of a DTI and tractography study. *Eur Radiol* 23, 57-64.

- de Wit, A. E., Booij, S. H., Giltay, E. J., Joffe, H., Schoevers, R. A., Oldehinkel, A. J., 2020. Association of use of oral contraceptives with depressive symptoms among adolescents and young women. *JAMA Psychiatry* 77, 52-59.
- Deci, P. A., Lydiard, R. B., Santos, A. B., Arana, G. W., 1992. Oral contraceptives and panic disorder. *J Clin Psychiatry* 53, 163-165.
- Del Río, J. P., Alliende, M. I., Molina, N., Serrano, F. G., Molina, S., Vigil, P., 2018. Steroid hormones and their action in women's brains: The importance of hormonal balance. *Front Public Health* 6, 141.
- Dreher, J. C., Schmidt, P. J., Kohn, P., Furman, D., Rubinow, D., Berman, K. F., 2007. Menstrual cycle phase modulates reward-related neural function in women. *Proc Natl Acad Sci U S A* 104, 2465-2470.
- Edwards, A. C., Lönn, S. L., Crump, C., Mościcki, E. K., Sundquist, J., Kendler, K. S., Sundquist, K., 2020. Oral contraceptive use and risk of suicidal behavior among young women. *Psychol Med*, 1-8.
- Estanislau, C., Ramos, A. C., Ferraresi, P. D., Costa, N. F., de Carvalho, H. M., Batistela, S., 2011. Individual differences in the elevated plus-maze and the forced swim test. *Behav Processes* 86, 46-51.
- Everitt, B. J., 1990. Sexual motivation: a neural and behavioural analysis of the mechanisms underlying appetitive and copulatory responses of male rats. *Neurosci Biobehav Rev* 14, 217-232.
- Finn, D. A., Phillips, T. J., Okorn, D. M., Chester, J. A., Cunningham, C. L., 1997. Rewarding effect of the neuroactive steroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in mice. *Pharmacol Biochem Behav* 56, 261-264.
- Fish, E. W., Faccidomo, S., DeBold, J. F., Miczek, K. A., 2001. Alcohol, allopregnanolone and aggression in mice. *Psychopharmacology (Berl)* 153, 473-483.
- Fish, E. W., Whitman, B. J., DiBerto, J. F., Robinson, J. E., Morrow, A. L., Malanga, C. J., 2014. Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice. *Psychopharmacology (Berl)* 231, 3415-3423.
- Follesa, P., Concas, A., Porcu, P., Sanna, E., Serra, M., Mostallino, M., Purdy, R., Biggio, G., 2001. Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. *Brain Research Reviews* 37, 81-90.
- Follesa, P., Porcu, P., Sogliano, C., Cinus, M., Biggio, F., Mancuso, L., Mostallino, M., Paoletti, A., Purdy, R., Biggio, G., Concas, A., 2002. Changes in GABA(A) receptor gamma 2 subunit gene expression induced by long-term administration of oral contraceptives in rats. *Neuropharmacology* 42, 325-336.

- Fruzzetti, F., Fidecicchi, T., 2020. Hormonal contraception and depression: Updated evidence and implications in clinical practice. *Clin Drug Investig* 40, 1097-1106.
- Frye, C. A., 2001. The role of neurosteroids and non-genomic effects of progestins and androgens in mediating sexual receptivity of rodents. *Brain Res Brain Res Rev* 37, 201-222.
- Frye, C. A., Bayon, L. E., Pursnani, N. K., Purdy, R. H., 1998. The neurosteroids, progesterone and 3alpha,5alpha-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. *Brain Res* 808, 72-83.
- Frye, C. A., Rhodes, M. E., 2006. Infusions of 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) to the ventral tegmental area, but not the substantia nigra, enhance exploratory, anti-anxiety, social and sexual behaviours and concomitantly increase 3alpha,5alpha-THP concentrations in the hippocampus, diencephalon and cortex of ovariectomised oestrogen-primed rats. *J Neuroendocrinol* 18, 960-975.
- Frye, C. A., Vongher, J. M., 2001. Ventral tegmental area infusions of inhibitors of the biosynthesis and metabolism of 3alpha,5alpha-THP attenuate lordosis of hormone-primed and behavioural oestrous rats and hamsters. *J Neuroendocrinol* 13, 1076-1086.
- Fénelon, V. S., Herbison, A. E., 1996. Plasticity in GABAA receptor subunit mRNA expression by hypothalamic magnocellular neurons in the adult rat. *J Neurosci* 16, 4872-4880.
- Ghazal, A. E., Makar, A. B., Daabees, T. T., 1976. Effect of oral contraceptives (Lyndiol) on rat brain gamma aminobutyric acid system. *Biochem Pharmacol* 25, 115-118.
- Gilman, D. P., Hitt, J. C., 1978. Effects of gonadal hormones on pacing of sexual contacts by female rats. *Behav Biol* 24, 77-87.
- Giraldi, A., Marson, L., Nappi, R., Pfaus, J., Traish, A. M., Vardi, Y., Goldstein, I., 2004. Physiology of female sexual function: animal models. *J Sex Med* 1, 237-253.
- Girdler, S. S., Lindgren, M., Porcu, P., Rubinow, D. R., Johnson, J. L., Morrow, A. L., 2012. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. *Psychoneuroendocrinology* 37, 543-553.
- Glaser, J. H., Etgen, A. M., Barfield, R. J., 1985. Intrahypothalamic effects of progestin agonists on estrous behavior and progestin receptor binding. *Physiol Behav* 34, 871-877.
- Gogos, A., 2013. Natural and synthetic sex hormones: effects on higher-order cognitive function and prepulse inhibition. *Biol Psychol* 93, 17-23.
- Gogos, A., Wu, Y. C., Williams, A. S., Byrne, L. K., 2014. The effects of ethinylestradiol and progestins ("the pill") on cognitive function in pre-menopausal women. *Neurochem Res* 39, 2288-2300.

- Gordon, H. W., Lee, P. A., 1993. No difference in cognitive performance between phases of the menstrual cycle. *Psychoneuroendocrinology* 18, 521-531.
- Graham, B. M., Milad, M. R., 2013. Blockade of estrogen by hormonal contraceptives impairs fear extinction in female rats and women. *Biol Psychiatry* 73, 371-378.
- Graham, C. A., Bancroft, J., Doll, H. A., Greco, T., Tanner, A., 2007. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? *Psychoneuroendocrinology* 32, 246-255.
- Graham, C. A., Ramos, R., Bancroft, J., Maglaya, C., Farley, T. M., 1995. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. *Contraception* 52, 363-369.
- Grant, A. D., Wilbrecht, I., Kriegsfeld, L. J., 2021. Adolescent development of biological rhythms in female rats: Estradiol dependence and effects of combined contraceptives. *Frontiers in Physiology* 12, 752363.
- Gravelsins, L., Duncan, K., Einstein, G., 2021. Do oral contraceptives affect young women's memory? Dopamine-dependent working memory is influenced by COMT genotype, but not time of pill ingestion. *PLoS One* 16, e0252807.
- Gregory, S. T., Hall, K., Quast, T., Gatto, A., Bleck, J., Storch, E. A., DeBate, R., 2018. Hormonal contraception, depression, and academic performance among females attending college in the United States. *Psychiatry Res* 270, 111-116.
- Griksiene, R., Monciunskaitė, R., Arnatkeviciute, A., Ruksenas, O., 2018. Does the use of hormonal contraceptives affect the mental rotation performance? *Horm Behav* 100, 29-38.
- Griksiene, R., Ruksenas, O., 2011. Effects of hormonal contraceptives on mental rotation and verbal fluency. *Psychoneuroendocrinology* 36, 1239-1248.
- Guida, M., Di Carlo, C., Troisi, J., Gallo, A., Cibarelli, F., Martini, E., Tiranini, L., Nappi, R. E., 2017. The sexuological impact of hormonal contraceptives based on their route of administration. *Gynecol Endocrinol* 33, 218-222.
- Guida, M., Di Spiezio Sardo, A., Bramante, S., Sparice, S., Acunzo, G., Tommaselli, G. A., Di Carlo, C., Pellicano, M., Greco, E., Nappi, C., 2005. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. *Hum Reprod* 20, 1100-1106.
- Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., Belelli, D., 2015. GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response. *Front Neuroendocrinol* 36, 28-48.

- Gurvich, C., Warren, A. M., Worsley, R., Hudaib, A. R., Thomas, N., Kulkarni, J., 2020. Effects of oral contraceptive androgenicity on visuospatial and social-emotional cognition: A prospective observational trial. *Brain Sci* 10, 194.
- Guy, A. J., Schuerch, F. S., Heffernan, S., Thomson, P. C., O'Brien, J. K., McGreevy, P. D., 2008. The effect of medroxyprogesterone acetate on behavioural responses of captive female hamadryas baboons (*Papio hamadryas*). *Anim Reprod Sci* 108, 412-424.
- Hall, K. S., White, K. O., Rickert, V. I., Reame, N., Westhoff, C., 2012. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. *Contraception* 86, 518-525.
- Hamstra, D. A., de Kloet, E. R., Quataert, I., Jansen, M., Van der Does, W., 2017. Mineralocorticoid receptor haplotype, estradiol, progesterone and emotional information processing. *Psychoneuroendocrinology* 76, 162-173.
- Hamstra, D. A., de Kloet, E. R., Tollenaar, M., Verkuil, B., Manai, M., Putman, P., Van der Does, W., 2016. Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing. *J Psychopharmacol* 30, 1054-1061.
- Hamstra, D. A., de Kloet, E. R., van Hemert, A. M., de Rijk, R. H., Van der Does, A. J., 2015. Mineralocorticoid receptor haplotype, oral contraceptives and emotional information processing. *Neuroscience* 286, 412-422.
- Hantsoo, L., Epperson, C. N., 2017. Anxiety disorders among women: A female lifespan approach. *Focus (Am Psychiatr Publ)* 15, 162-172.
- Henderson, J. A., Shively, C. A., 2004. Triphasic oral contraceptive treatment alters the behavior and neurobiology of female cynomolgus monkeys. *Psychoneuroendocrinology* 29, 21-34.
- Henderson, L. P., 2007. Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: effects on reproductive function. *Neuropharmacology* 52, 1439-1453.
- Hinderaker, K., Allen, A. M., Tosun, N., al'Absi, M., Hatsukami, D., Allen, S. S., 2015. The effect of combination oral contraceptives on smoking-related symptomatology during short-term smoking abstinence. *Addict Behav* 41, 148-151.
- Ho, H. P., Olsson, M., Westberg, L., Melke, J., Eriksson, E., 2001. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability? *Neuropsychopharmacology* 24, 502-510.

- Huang, M., Li, G., Liu, J., Li, Y., Du, P., 2020. Is there an association between contraception and sexual dysfunction in women? A systematic review and meta-analysis based on female sexual function index. *J Sex Med* 17, 1942-1955.
- Hwang, W. J., Lee, T. Y., Kim, N. S., Kwon, J. S., 2020. The role of estrogen receptors and their signaling across psychiatric disorders. *Int J Mol Sci* 22.
- Islam, F., Sparkes, C., Roodenrys, S., Astheimer, L., 2008. Short-term changes in endogenous estrogen levels and consumption of soy isoflavones affect working and verbal memory in young adult females. *Nutr Neurosci* 11, 251-262.
- Jacobs, A. J., Odom, M. J., Word, R. A., Carr, B. R., 1989. Effect of oral contraceptives on adrenocorticotropin and growth hormone secretion following CRH and GHRH administration. *Contraception* 40, 691-699.
- Johansson, I. M., Birzniece, V., Lindblad, C., Olsson, T., Bäckström, T., 2002. Allopregnanolone inhibits learning in the Morris water maze. *Brain Res* 934, 125-131.
- Jori, A., Dolfini, E., 1976. Modifications of striatal dopamine levels by steroid contraceptive drugs in mice and rats. *Neuroendocrinology* 21, 74-78.
- Juhász, G., Hullam, G., Eszlari, N., Gonda, X., Antal, P., Anderson, I. M., Hökfelt, T. G., Deakin, J. F., Bagdy, G., 2014. Brain galanin system genes interact with life stresses in depression-related phenotypes. *Proc Natl Acad Sci U S A* 111, E1666-1673.
- Keyes, K. M., Cheslack-Postava, K., Westhoff, C., Heim, C. M., Haloosim, M., Walsh, K., Koenen, K., 2013. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. *Am J Epidemiol* 178, 1378-1388.
- Kimmig, A. S., Wildgruber, D., Wendel, S. U., Sundström-Poromaa, I., Derntl, B., 2021. Friend vs. foe: Cognitive and affective empathy in women with different hormonal states. *Front Neurosci* 15, 608768.
- Kirschbaum, C., Kudielka, B. M., Gaab, J., Schommer, N. C., Hellhammer, D. H., 1999. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. *Psychosom Med* 61, 154-162.
- Kirschbaum, C., Pirke, K. M., Hellhammer, D. H., 1995. Preliminary evidence for reduced cortisol responsivity to psychological stress in women using oral contraceptive medication. *Psychoneuroendocrinology* 20, 509-514.
- Koolhaas, J. M., Schuurman, T., Wiepkema, P. R., 1980. The organization of intraspecific agonistic behaviour in the rat. *Prog Neurobiol* 15, 247-268.

- Kuehner, C., 2017. Why is depression more common among women than among men? *Lancet Psychiatry* 4, 146-158.
- Kuhl, H., Weber, W., Mehlis, W., Sandow, J., Taubert, H. D., 1984. Time- and dose-dependent alterations of basal and LH-RH-stimulated LH-release during treatment with various hormonal contraceptives. *Contraception* 30, 467-482.
- Kulkarni, J., 2007. Depression as a side effect of the contraceptive pill. *Expert Opin Drug Saf* 6, 371-374.
- Kumsta, R., Entringer, S., Hellhammer, D. H., Wüst, S., 2007. Cortisol and ACTH responses to psychosocial stress are modulated by corticosteroid binding globulin levels. *Psychoneuroendocrinology* 32, 1153-1157.
- Kurshan, N., Epperson, C. N., 2006. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. *Arch Womens Ment Health* 9, 1-14.
- Ladinsky, H., Consolo, S., Bianchi, S., Peri, G., Garattini, S., 1976. Lack of influence of the phase of estrus cycle or treatment with steroid contraceptive drugs on cholinergic parameters in mouse and rat brain. *Pharmacology* 14, 232-239.
- Lemus, A. E., Vilchis, F., Damsky, R., Chávez, B. A., García, G. A., Grillasca, I., Pérez-Palacios, G., 1992. Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. *J Steroid Biochem Mol Biol* 41, 881-890.
- Lewis, C. A., Kimmig, A. S., Zsido, R. G., Jank, A., Derntl, B., Sacher, J., 2019. Effects of hormonal contraceptives on mood: A focus on emotion recognition and reactivity, reward processing, and stress response. *Curr Psychiatry Rep* 21, 115.
- Lisofsky, N., Riediger, M., Gallinat, J., Lindenberger, U., Kühn, S., 2016. Hormonal contraceptive use is associated with neural and affective changes in healthy young women. *Neuroimage* 134, 597-606.
- Lobo, R. A., Stanczyk, F. Z., 1994. New knowledge in the physiology of hormonal contraceptives. *Am J Obstet Gynecol* 170, 1499-1507.
- Locci, A., Porcu, P., Talani, G., Santoru, F., Berretti, R., Giunti, E., Licheri, V., Sanna, E., Concas, A., 2017. Neonatal estradiol exposure to female rats changes GABA(A) receptor expression and function, and spatial learning during adulthood. *Hormones and Behavior* 87, 35-46.
- Lovick, T. A., Griffiths, J. L., Dunn, S. M., Martin, I. L., 2005. Changes in GABA(A) receptor subunit expression in the midbrain during the oestrous cycle in Wistar rats. *Neuroscience* 131, 397-405.
- Lundin, C., Danielsson, K. G., Bixo, M., Moby, L., Bengtsson, H., Jawad, I., Marions, L., Brynhildsen, J., Malmberg, A., Lindh, I., Sundström Poromaa, I., 2017. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the

- treatment cycle-A double-blind, placebo-controlled randomized trial. *Psychoneuroendocrinology* 76, 135-143.
- Maeng, L. Y., Milad, M. R., 2015. Sex differences in anxiety disorders: Interactions between fear, stress, and gonadal hormones. *Horm Behav* 76, 106-117.
- Maguire, J., Mody, I., 2008. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. *Neuron* 59, 207-213.
- Maguire, J. L., Stell, B. M., Rafizadeh, M., Mody, I., 2005. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. *Nat Neurosci* 8, 797-804.
- Maher, E. E., Overby, P. F., Bull, A. H., Beckmann, J. S., Leyrer-Jackson, J. M., Koebele, S. V., Bimonte-Nelson, H. A., Gipson, C. D., 2021. Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats. *Neuropharmacology* 198, 108756.
- Malmborg, A., Brynte, L., Falk, G., Brynhildsen, J., Hammar, M., Berterö, C., 2020. Sexual function changes attributed to hormonal contraception use - a qualitative study of women experiencing negative effects. *Eur J Contracept Reprod Health Care* 25, 169-175.
- Marchi, M., Cugurra, F., 1974. The effect of long-term oral treatment of rats with contraceptive steroids on tissue MAO. *Eur J Pharmacol* 25, 407-410.
- McEwen, B. S., Milner, T. A., 2017. Understanding the broad influence of sex hormones and sex differences in the brain. *J Neurosci Res* 95, 24-39.
- McIntyre, K. L., Porter, D. M., Henderson, L. P., 2002. Anabolic androgenic steroids induce age-, sex-, and dose-dependent changes in GABA(A) receptor subunit mRNAs in the mouse forebrain. *Neuropharmacology* 43, 634-645.
- Meltzer-Brody, S., Colquhoun, H., Riesenberger, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., Jonas, J., Kaner, S., 2018. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet* 392, 1058-1070.
- Mennenga, S. E., Gerson, J. E., Koebele, S. V., Kingston, M. L., Tsang, C. W., Engler-Chiurazzi, E. B., Baxter, L. C., Bimonte-Nelson, H. A., 2015. Understanding the cognitive impact of the contraceptive estrogen Ethinyl Estradiol: tonic and cyclic administration impairs memory, and performance correlates with basal forebrain cholinergic system integrity. *Psychoneuroendocrinology* 54, 1-13.

- Mihalik, J. P., Ondrak, K. S., Guskiewicz, K. M., McMurray, R. G., 2009. The effects of menstrual cycle phase on clinical measures of concussion in healthy college-aged females. *J Sci Med Sport* 12, 383-387.
- Milad, M. R., Igoe, S. A., Lebron-Milad, K., Novales, J. E., 2009. Estrous cycle phase and gonadal hormones influence conditioned fear extinction. *Neuroscience* 164, 887-895.
- Mitchell, V., Welling, L., 2020. Not all progestins are created equally: Considering unique progestins individually in psychobehavioral research. *Adaptive Human Behavior and Physiology* 6, 381-412.
- Modol, L., Casas, C., Navarro, X., Llidó, A., Vallée, M., Pallarès, M., Darbra, S., 2014. Neonatal finasteride administration alters hippocampal $\alpha 4$ and δ GABAAR subunits expression and behavioural responses to progesterone in adult rats. *Int J Neuropsychopharmacol* 17, 259-273.
- Molendijk, M. L., de Kloet, E. R., 2015. Immobility in the forced swim test is adaptive and does not reflect depression. *Psychoneuroendocrinology* 62, 389-391.
- Mordecai, K. L., Rubin, L. H., Maki, P. M., 2008. Effects of menstrual cycle phase and oral contraceptive use on verbal memory. *Horm Behav* 54, 286-293.
- Morrow, A. L., Boero, G., Porcu, P., 2020. A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies. *Alcohol Clin Exp Res* 44, 320-339.
- Morrow, A. L., Porcu, P., Boyd, K. N., Grant, K. A., 2006. Hypothalamic-pituitary-adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. *Dialogues in clinical neuroscience* 8, 463-477.
- Morssinkhof, M. W. L., Lamers, F., Hoogendoorn, A. W., de Wit, A. E., Riese, H., Giltay, E. J., van den Heuvel, O. A., Penninx, B. W., Broekman, B. F. P., 2021. Oral contraceptives, depressive and insomnia symptoms in adult women with and without depression. *Psychoneuroendocrinology* 133, 105390.
- Nadler, R. D., Dahl, J. F., Collins, D. C., Gould, K. G., 1992. Hormone levels and anogenital swelling of female chimpanzees as a function of estrogen dosage in a combined oral contraceptive. *Proc Soc Exp Biol Med* 201, 73-79.
- Naert, G., Maurice, T., Tapia-Arancibia, L., Givalois, L., 2007. Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. *Psychoneuroendocrinology* 32, 1062-1078.
- Nappi, R. E., Serrani, M., Jensen, J. T., 2014. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. *Int J Womens Health* 6, 711-718.

- Neumann, A. M., Schmidt, C. X., Brockmann, R. M., Oster, H., 2019. Circadian regulation of endocrine systems. *Auton Neurosci* 216, 1-8.
- Nouri, S., Biedermann, S. V., Joue, G., Auer, M. K., Sommer, T., Fuss, J., 2022. Effects of circulating estradiol on physiological, behavioural, and subjective correlates of anxiety: A double-blind, randomized, placebo-controlled trial. *Psychoneuroendocrinology* 138, 105682.
- Oinonen, K. A., Mazmanian, D., 2002. To what extent do oral contraceptives influence mood and affect? *J Affect Disord* 70, 229-240.
- Paoletti, A. M., Lello, S., Fratta, S., Orrù, M., Ranuzzi, F., Sogliano, C., Concas, A., Biggio, G., Melis, G. B., 2004. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol. *Fertil Steril* 81, 645-651.
- Pastor, Z., Holla, K., Chmel, R., 2013. The influence of combined oral contraceptives on female sexual desire: a systematic review. *Eur J Contracept Reprod Health Care* 18, 27-43.
- Petersen, N., Kilpatrick, L. A., Goharзад, A., Cahill, L., 2014. Oral contraceptive pill use and menstrual cycle phase are associated with altered resting state functional connectivity. *Neuroimage* 90, 24-32.
- Petersen, N., Touroutoglou, A., Andreano, J. M., Cahill, L., 2015. Oral contraceptive pill use is associated with localized decreases in cortical thickness. *Hum Brain Mapp* 36, 2644-2654.
- Pibiri, F., Nelson, M., Guidotti, A., Costa, E., Pinna, G., 2008. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder. *Proc Natl Acad Sci U S A* 105, 5567-5572.
- Picazo, O., Fernández-Guasti, A., Lemus, A. E., García, G. A., 1998. A-ring reduced derivatives of two synthetic progestins induce anxiolytic effects in ovariectomized rats. *Brain Res* 796, 45-52.
- Pinna, G., Dong, E., Matsumoto, K., Costa, E., Guidotti, A., 2003. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. *Proc Natl Acad Sci U S A* 100, 2035-2040.
- Plamberger, C. P., Van Wijk, H. E., Kerschbaum, H., Pletzer, B. A., Gruber, G., Oberascher, K., Dresler, M., Hahn, M. A., Hoedlmoser, K., 2021. Impact of menstrual cycle phase and oral contraceptives on sleep and overnight memory consolidation. *J Sleep Res* 30, e13239.
- Pletzer, B., Crone, J. S., Kronbichler, M., Kerschbaum, H., 2016. Menstrual cycle and hormonal contraceptive-dependent changes in intrinsic connectivity of resting-state brain networks correspond to behavioral changes due to hormonal status. *Brain Connect* 6, 572-585.

- Pletzer, B., Harris, T., Hidalgo-Lopez, E., 2019. Previous contraceptive treatment relates to grey matter volumes in the hippocampus and basal ganglia. *Sci Rep* 9, 11003.
- Pletzer, B., Kronbichler, M., Aichhorn, M., Bergmann, J., Ladurner, G., Kerschbaum, H. H., 2010. Menstrual cycle and hormonal contraceptive use modulate human brain structure. *Brain Res* 1348, 55-62.
- Pletzer, B. A., Kerschbaum, H. H., 2014. 50 years of hormonal contraception - time to find out, what it does to our brain. *Front Neurosci* 8, 256.
- Pluchino, N., Cubeddu, A., Begliuomini, S., Merlini, S., Giannini, A., Bucci, F., Casarosa, E., Luisi, M., Cela, V., Genazzani, A. R., 2009. Daily variation of brain-derived neurotrophic factor and cortisol in women with normal menstrual cycles, undergoing oral contraception and in postmenopause. *Hum Reprod* 24, 2303-2309.
- Porcu, P., Barron, A. M., Frye, C. A., Walf, A. A., Yang, S. Y., He, X. Y., Morrow, A. L., Panzica, G. C., Melcangi, R. C., 2016. Neurosteroidogenesis today: Novel targets for neuroactive steroid synthesis and action and their relevance for translational research. *Journal of Neuroendocrinology* 28, 19.
- Porcu, P., Morrow, A. L., 2014. Divergent neuroactive steroid responses to stress and ethanol in rat and mouse strains: relevance for human studies. *Psychopharmacology* 231, 3257-3272.
- Porcu, P., Mostallino, M. C., Sogliano, C., Santoru, F., Berretti, R., Concas, A., 2012. Long-term administration with levonorgestrel decreases allopregnanolone levels and alters GABA(A) receptor subunit expression and anxiety-like behavior. *Pharmacology Biochemistry and Behavior* 102, 366-372.
- Porcu, P., Serra, M., Concas, A., 2019. The brain as a target of hormonal contraceptives: Evidence from animal studies. *Front Neuroendocrinol* 55, 100799.
- Porsolt, R. D., Bertin, A., Jalfre, M., 1977. Behavioral despair in mice: a primary screening test for antidepressants. *Arch Int Pharmacodyn Ther* 229, 327-336.
- Rabe, T., Kowald, A., Ortmann, J., Rehberger-Schneider, S., 2000. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. *Gynecol Endocrinol* 14, 223-230.
- Rapkin, A. J., Biggio, G., Concas, A., 2006a. Oral contraceptives and neuroactive steroids. *Pharmacol Biochem Behav* 84, 628-634.
- Rapkin, A. J., Morgan, M., Sogliano, C., Biggio, G., Concas, A., 2006b. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. *Fertil Steril* 85, 1371-1378.

- Rasmusson, A. M., Marx, C. E., Pineles, S. L., Locci, A., Scioli-Salter, E. R., Nillni, Y. I., Liang, J. J., Pinna, G., 2017. Neuroactive steroids and PTSD treatment. *Neurosci Lett* 649, 156-163.
- Regidor, P. A., 2018. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. *Oncotarget* 9, 34628-34638.
- Reynolds, R. M., Hii, H. L., Pennell, C. E., McKeague, I. W., de Kloet, E. R., Lye, S., Stanley, F. J., Mattes, E., Foster, J. K., 2013. Analysis of baseline hypothalamic-pituitary-adrenal activity in late adolescence reveals gender specific sensitivity of the stress axis. *Psychoneuroendocrinology* 38, 1271-1280.
- Robakis, T., Williams, K. E., Nutkiewicz, L., Rasgon, N. L., 2019. Hormonal contraceptives and mood: Review of the literature and implications for future research. *Curr Psychiatry Rep* 21, 57.
- Roche, D. J., King, A. C., Cohoon, A. J., Lovallo, W. R., 2013. Hormonal contraceptive use diminishes salivary cortisol response to psychosocial stress and naltrexone in healthy women. *Pharmacol Biochem Behav* 109, 84-90.
- Rosenberg, L., Park, S., 2002. Verbal and spatial functions across the menstrual cycle in healthy young women. *Psychoneuroendocrinology* 27, 835-841.
- Salonia, A., Nappi, R. E., Pontillo, M., Daverio, R., Smeraldi, A., Briganti, A., Fabbri, F., Zanni, G., Rigatti, P., Montorsi, F., 2005. Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. *Horm Behav* 47, 164-169.
- Sanders, S. A., Graham, C. A., Bass, J. L., Bancroft, J., 2001. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. *Contraception* 64, 51-58.
- Sanna, E., Mostallino, M. C., Murru, L., Carta, M., Talani, G., Zucca, S., Mura, M. L., Maciocco, E., Biggio, G., 2009. Changes in expression and function of extrasynaptic GABAA receptors in the rat hippocampus during pregnancy and after delivery. *J Neurosci* 29, 1755-1765.
- Santoru, F., Berretti, R., Locci, A., Porcu, P., Concas, A., 2014. Decreased allopregnanolone induced by hormonal contraceptives is associated with a reduction in social behavior and sexual motivation in female rats. *Psychopharmacology* 231, 3351-3364.
- Sassoè-Pognetto, M., Follesa, P., Panzanelli, P., Perazzini, A.-Z., Porcu, P., Sogliano, C., Cherchi, C., Concas, A., 2007. Fluctuations in brain concentrations of neurosteroids are not associated to changes in gephyrin levels. *Brain Research* 1169, 1-8.
- Schaffir, J., Worly, B. L., Gur, T. L., 2016. Combined hormonal contraception and its effects on mood: a critical review. *Eur J Contracept Reprod Health Care* 21, 347-355.

- Scharfman, H. E., Mercurio, T. C., Goodman, J. H., Wilson, M. A., MacLusky, N. J., 2003. Hippocampal excitability increases during the estrous cycle in the rat: a potential role for brain-derived neurotrophic factor. *J Neurosci* 23, 11641-11652.
- Scheele, D., Plota, J., Stoffel-Wagner, B., Maier, W., Hurlemann, R., 2016. Hormonal contraceptives suppress oxytocin-induced brain reward responses to the partner's face. *Soc Cogn Affect Neurosci* 11, 767-774.
- Scheuringer, A., Lundin, C., Derntl, B., Pletzer, B., Sundström Poromaa, I., 2020. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women. *Psychoneuroendocrinology* 113, 104544.
- Segebladh, B., Borgström, A., Odling, V., Bixo, M., Sundström-Poromaa, I., 2009. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives. *Contraception* 79, 50-55.
- Serra, M., Sanna, E., Mostallino, M. C., Biggio, G., 2007. Social isolation stress and neuroactive steroids. *Eur Neuropsychopharmacol* 17, 1-11.
- Sharma, R., Fang, Z., Smith, A., Ismail, N., 2020a. Oral contraceptive use, especially during puberty, alters resting state functional connectivity. *Horm Behav* 126, 104849.
- Sharma, R., Smith, S. A., Boukina, N., Dordari, A., Mistry, A., Taylor, B. C., Felix, N., Cameron, A., Fang, Z., Smith, A., Ismail, N., 2020b. Use of the birth control pill affects stress reactivity and brain structure and function. *Horm Behav* 124, 104783.
- Shen, H., Gong, Q. H., Aoki, C., Yuan, M., Ruderman, Y., Dattilo, M., Williams, K., Smith, S. S., 2007. Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. *Nat Neurosci* 10, 469-477.
- Shen, H., Gong, Q. H., Yuan, M., Smith, S. S., 2005. Short-term steroid treatment increases delta GABAA receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. *Neuropharmacology* 49, 573-586.
- Sieghart, W., Savić, M. M., 2018. International Union of Basic and Clinical Pharmacology. CVI: GABA. *Pharmacol Rev* 70, 836-878.
- Silber, M., Almkvist, O., Larsson, B., Stock, S., Uvnäs-Moberg, K., 1987. The effect of oral contraceptive pills on levels of oxytocin in plasma and on cognitive functions. *Contraception* 36, 641-650.
- Simone, J., Bogue, E. A., Bhatti, D. L., Day, L. E., Farr, N. A., Grossman, A. M., Holmes, P. V., 2015. Ethinyl estradiol and levonorgestrel alter cognition and anxiety in rats concurrent with a decrease in

- tyrosine hydroxylase expression in the locus coeruleus and brain-derived neurotrophic factor expression in the hippocampus. *Psychoneuroendocrinology* 62, 265-278.
- Sinnott, R. S., Mark, G. P., Finn, D. A., 2002. Reinforcing effects of the neurosteroid allopregnanolone in rats. *Pharmacol Biochem Behav* 72, 923-929.
- Sitruk-Ware, R., Nath, A., 2010. The use of newer progestins for contraception. *Contraception* 82, 410-417.
- Skovlund, C. W., Mørch, L. S., Kessing, L. V., Lange, T., Lidegaard, Ø., 2018. Association of hormonal contraception with suicide attempts and suicides. *Am J Psychiatry* 175, 336-342.
- Skovlund, C. W., Mørch, L. S., Kessing, L. V., Lidegaard, Ø., 2016. Association of hormonal contraception with depression. *JAMA Psychiatry* 73, 1154-1162.
- Slattery, J., Morales, D., Pinheiro, L., Kurz, X., 2018. Cohort study of psychiatric adverse events following exposure to levonorgestrel-containing intrauterine devices in UK general practice. *Drug Saf* 41, 951-958.
- Smith, N. K., Jozkowski, K. N., Sanders, S. A., 2014. Hormonal contraception and female pain, orgasm and sexual pleasure. *J Sex Med* 11, 462-470.
- Smith, S. S., Gong, Q. H., Li, X., Moran, M. H., Bitran, D., Frye, C. A., Hsu, F. C., 1998. Withdrawal from 3alpha-OH-5alpha-pregnan-20-one using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor alpha4 subunit in association with increased anxiety. *J Neurosci* 18, 5275-5284.
- Sohrabji, F., Miranda, R. C., Toran-Allerand, C. D., 1995. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. *Proc Natl Acad Sci U S A* 92, 11110-11114.
- Soma, K. K., Scotti, M. A., Newman, A. E., Charlier, T. D., Demas, G. E., 2008. Novel mechanisms for neuroendocrine regulation of aggression. *Front Neuroendocrinol* 29, 476-489.
- Stock, S., Karlsson, R., von Schoultz, B., 1994. Serum profiles of oxytocin during oral contraceptive treatment. *Gynecol Endocrinol* 8, 121-126.
- Strojny, J., Domes, G., Fischbacher, U., von Dawans, B., 2021. The modulation of social behavior and empathy via oral contraceptives and female sex hormones. *Psychoneuroendocrinology* 131, 105250.
- Strufaldi, R., Pompei, L. M., Steiner, M. L., Cunha, E. P., Ferreira, J. A., Peixoto, S., Fernandes, C. E., 2010. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. *Contraception* 82, 147-154.

- Stuckey, B. G., 2008. Female sexual function and dysfunction in the reproductive years: the influence of endogenous and exogenous sex hormones. *J Sex Med* 5, 2282-2290.
- Sundstrom Poromaa, I., Segebladh, B., 2012. Adverse mood symptoms with oral contraceptives. *Acta Obstet Gynecol Scand* 91, 420-427.
- Taylor, C. M., Pritschet, L., Jacobs, E. G., 2021. The scientific body of knowledge - Whose body does it serve? A spotlight on oral contraceptives and women's health factors in neuroimaging. *Front Neuroendocrinol* 60, 100874.
- Tellería, C. M., Carrizo, D. G., Deis, R. P., 1994. Levonorgestrel inhibits luteinizing hormone-stimulated progesterone production in rat luteal cells. *J Steroid Biochem Mol Biol* 50, 161-166.
- Thomas, J., Météreau, E., Déchaud, H., Pugeat, M., Dreher, J. C., 2014. Hormonal treatment increases the response of the reward system at the menopause transition: a counterbalanced randomized placebo-controlled fMRI study. *Psychoneuroendocrinology* 50, 167-180.
- Toffol, E., Heikinheimo, O., Koponen, P., Luoto, R., Partonen, T., 2012. Further evidence for lack of negative associations between hormonal contraception and mental health. *Contraception* 86, 470-480.
- United Nations. Population Division, 2019. Contraceptive Use by Method 2019 Data Booklet [WWW Document]. URL https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf.
- Uzunova, V., Sheline, Y., Davis, J. M., Rasmusson, A., Uzunov, D. P., Costa, E., Guidotti, A., 1998. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. *Proc Natl Acad Sci U S A* 95, 3239-3244.
- Van de Poll, N. E., Tamini, M. S., Endert, E., Louwerse, A. L., 1988. Gonadal steroid influence upon sexual and aggressive behavior of female rats. *Int J Neurosci* 41, 271-286.
- Vetter-O'Hagen, C. S., Spear, L. P., 2012. Hormonal and physical markers of puberty and their relationship to adolescent-typical novelty-directed behavior. *Dev Psychobiol* 54, 523-535.
- Wagner, K. D., Berenson, A. B., 1994. Norplant-associated major depression and panic disorder. *J Clin Psychiatry* 55, 478-480.
- Wallwiener, M., Wallwiener, L. M., Seeger, H., Mueck, A. O., Zipfel, S., Bitzer, J., Wallwiener, C. W., 2010. Effects of sex hormones in oral contraceptives on the female sexual function score: a study in German female medical students. *Contraception* 82, 155-159.

- Wharton, W., Hirshman, E., Merritt, P., Doyle, L., Paris, S., Gleason, C., 2008. Oral contraceptives and androgenicity: influences on visuospatial task performance in younger individuals. *Exp Clin Psychopharmacol* 16, 156-164.
- Wiegatz, I., Kutschera, E., Lee, J. H., Moore, C., Mellinger, U., Winkler, U. H., Kuhl, H., 2003. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. *Contraception* 67, 25-32.
- Williams, B. N., Jauk, V. C., Szychowski, J. M., Arbuckle, J. L., 2021. Adolescent emergency contraception usage, knowledge, and perception. *Contraception* 103, 361-366.
- Willner, P., 1997. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. *Psychopharmacology (Berl)* 134, 319-329.
- Yoest, K. E., Cummings, J. A., Becker, J. B., 2014. Estradiol, dopamine and motivation. *Cent Nerv Syst Agents Med Chem* 14, 83-89.
- Zettermark, S., Perez Vicente, R., Merlo, J., 2018. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women. *PLoS One* 13, e0194773.